Compensatory mutations restore fitness during the evolution of dihydrofolate reductase.
Whether a trade-off exists between robustness and evolvability is an important issue for protein evolution. Although traditional viewpoints have assumed that existing functions must be compromised by the evolution of novel activities, recent research has suggested that existing phenotypes can be robust to the evolution of novel protein functions. Enzymes that are targets of antibiotics that are competitive inhibitors must evolve decreased drug affinity while maintaining their function and sustaining growth. Utilizing a transgenic Saccharomyces cerevisiae model expressing the dihydrofolate reductase (DHFR) enzyme from the malarial parasite Plasmodium falciparum, we examine the robustness of growth rate to drug-resistance mutations. We assay the growth rate and resistance of all 48 combinations of 6 DHFR point mutations associated with increased drug resistance in field isolates of the parasite. We observe no consistent relationship between growth rate and resistance phenotypes among the DHFR alleles. The three evolutionary pathways that dominate DHFR evolution show that mutations with increased resistance can compensate for initial declines in growth rate from previously acquired mutations. In other words, resistance mutations that occur later in evolutionary trajectories can compensate for the fitness consequences of earlier mutations. Our results suggest that high levels of resistance may be selected for without necessarily jeopardizing overall fitness.
Brown
Kyle M
KM
Department of Organismic and Evolutionary Biology, Harvard University, MA, USA. kylemichaelbrown@gmail.com
Costanzo
Marna S
MS
Xu
Wenxin
W
Roy
Scott
S
Lozovsky
Elena R
ER
Hartl
Daniel L
DL
D000483:Alleles; D000962:Antimalarials / Q000494:pharmacology*; D004351:Drug Resistance; D019143:Evolution, Molecular; D017125:Genes, Protozoan; D056084:Genetic Fitness; D008957:Models, Genetic; D010641:Phenotype; D010963:Plasmodium falciparum / Q000201:enzymology / Q000235:genetics*; D017354:Point Mutation; D011739:Pyrimethamine / Q000494:pharmacology*; D012441:Saccharomyces cerevisiae / Q000201:enzymology / Q000235:genetics; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics* / Q000378:metabolism
D000962:Antimalarials; D013762:Tetrahydrofolate Dehydrogenase; D011739:Pyrimethamine